Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations.

Greil R, Pleyer L, Jansko B, Feierabend C, Rettenbacher L, Stiefel O, Rass C, Morre P, Neureiter D, Greil-Ressler S.

Oncotarget. 2018 Apr 17;9(29):20928-20940. doi: 10.18632/oncotarget.25037. eCollection 2018 Apr 17.

2.

A phase I study of an oral simulated FOLFOX with high dose capecitabine.

Mulkerin D, LoConte NK, Holen KD, Thomas JP, Alberti D, Marnocha R, Kolesar J, Eickhoff J, Oliver K, Feierabend C, Wilding G.

Invest New Drugs. 2009 Oct;27(5):461-8. doi: 10.1007/s10637-008-9210-8. Epub 2009 Jan 8.

3.

Phase I study of docetaxel and topotecan in patients with advanced malignancies.

Dubey S, Hutson P, Alberti D, Arzoomanian R, Binger K, Volkman J, Feierabend C, Wilding G, Schiller JH.

J Oncol Pharm Pract. 2005 Dec;11(4):131-8.

PMID:
16595064
4.

Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study.

Schulz CA, Mehta MP, Badie B, McGinn CJ, Robins HI, Hayes L, Chappell R, Volkman J, Binger K, Arzoomanian R, Simon K, Alberti D, Feierabend C, Tutsch KD, Kunugi KA, Wilding G, Kinsella TJ.

Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):1107-15.

PMID:
15234045
5.

A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.

Bailey HH, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Marnocha R, Holstein SA, Stewart J, Lewis KA, Hohl RJ.

Cancer Chemother Pharmacol. 2004 Oct;54(4):368-76. Epub 2004 Jun 15.

PMID:
15205914
6.

Phase I trial of the polyamine analog N1,N14-diethylhomospermine (DEHSPM) in patients with advanced solid tumors.

Wilding G, King D, Tutsch K, Pomplun M, Feierabend C, Alberti D, Arzoomanian R.

Invest New Drugs. 2004 Apr;22(2):131-8.

PMID:
14739661
7.

Phase I trial of perillyl alcohol administered four times daily continuously.

Morgan-Meadows S, Dubey S, Gould M, Tutsch K, Marnocha R, Arzoomanin R, Alberti D, Binger K, Feierabend C, Volkman J, Ellingen S, Black S, Pomplun M, Wilding G, Bailey H.

Cancer Chemother Pharmacol. 2003 Nov;52(5):361-6. Epub 2003 Aug 2.

PMID:
12904896
8.

Gemcitabine, Paclitaxel, and piritrexim: a phase I study.

Liu G, Bailey HH, Arzoomanian RZ, Alberti D, Binger K, Volkman J, Feierabend C, Marnocha R, Wilding G, Thomas JP.

Am J Clin Oncol. 2003 Jun;26(3):280-4.

PMID:
12796601
9.

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol.

Thomas JP, Tutsch KD, Cleary JF, Bailey HH, Arzoomanian R, Alberti D, Simon K, Feierabend C, Binger K, Marnocha R, Dresen A, Wilding G.

Cancer Chemother Pharmacol. 2002 Dec;50(6):465-72. Epub 2002 Oct 2.

PMID:
12451473
10.

Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy.

Morgan-Meadows S, Thomas JP, Mulkerin D, Berlin JD, Bailey H, Binger K, Volkman J, Alberti D, Feierabend C, Marrocha R, Arzoomanian RZ, Wilding G.

Invest New Drugs. 2002 Nov;20(4):377-82.

PMID:
12448654
11.

Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats.

Merchant J, Tutsch K, Dresen A, Arzoomanian R, Alberti D, Feierabend C, Binger K, Marnoccha R, Thomas J, Cleary J, Wilding G.

Clin Cancer Res. 2002 Jul;8(7):2193-201.

12.

Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy.

Liu G, Berlin J, Tutsch KD, Van Ummersen L, Dresen A, Marnocha R, Arzomanian R, Alberti D, Feierabend C, Binger K, Wilding G.

Clin Cancer Res. 2002 Mar;8(3):706-11.

13.

Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food.

Berlin J, Tutsch KD, Arzoomanian RZ, Alberti D, Binger K, Feierabend C, Dresen A, Marnocha R, Pluda J, Wilding G.

Clin Cancer Res. 2002 Jan;8(1):86-94.

14.

Phase I clinical and pharmacokinetic trial of irofulven.

Thomas JP, Arzoomanian R, Alberti D, Feierabend C, Binger K, Tutsch KD, Steele T, Marnocha R, Smith C, Smith S, MacDonald J, Wilding G, Bailey H.

Cancer Chemother Pharmacol. 2001 Dec;48(6):467-72.

PMID:
11800027
15.

Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.

Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Binger K, Tutsch KD, Pomplun M, Wahamaki A, Marnocha R, Wilding G, Bailey HH.

Clin Cancer Res. 2000 Feb;6(2):390-6.

16.

Phase I trial of intravenous thymidine and carboplatin in patients with advanced cancer.

Robins HI, Tutsch K, Katschinski DM, Jacobson E, Mehta M, Olsen M, Cohen JD, Tiggelaar CL, Arzoomanian RZ, Alberti D, Feierabend C, Wilding G.

J Clin Oncol. 1999 Sep;17(9):2922-31.

PMID:
10561372
17.

Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812).

Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Feierabend C, Robins HI, Spriggs DR, Wilding G.

Invest New Drugs. 1999;17(1):63-72.

PMID:
10555124
18.

A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors.

Berlin JD, Alberti DB, Arzoomanian RZ, Feierabend CA, Simon KJ, Binger KA, Marnocha RM, Wilding G.

Invest New Drugs. 1998-1999;16(4):325-30.

PMID:
10426665
19.

A pilot study of melphalan, tumor necrosis factor-alpha and 41.8 degrees C whole-body hyperthermia.

Robins HI, Katschinski DM, Longo W, Grosen E, Wilding G, Gillis W, Kraemer C, Tiggelaar CL, Rushing D, Stewart JA, Spriggs D, Love R, Arzoomanian RZ, Feierabend C, Alberti D, Morgan K, Simon K, d'Oleire F.

Cancer Chemother Pharmacol. 1999;43(5):409-14.

PMID:
10100597
20.

Phase I clinical trial of perillyl alcohol administered daily.

Ripple GH, Gould MN, Stewart JA, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Pomplun M, Wilding G, Bailey HH.

Clin Cancer Res. 1998 May;4(5):1159-64.

21.

Phase I clinical and pharmacokinetic trial of penclomedine using a novel, two-stage trial design for patients with advanced malignancy.

Berlin J, Stewart JA, Storer B, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Wilding G.

J Clin Oncol. 1998 Mar;16(3):1142-9.

PMID:
9508201
22.

Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan.

Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun M, Mulcahy RT, Wilding G.

J Natl Cancer Inst. 1997 Dec 3;89(23):1789-96.

PMID:
9392620
23.

Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor.

Berlin J, Tutsch KD, Hutson P, Cleary J, Rago RP, Arzoomanian RZ, Alberti D, Feierabend C, Wilding G.

J Clin Oncol. 1997 Feb;15(2):781-9.

PMID:
9053505
24.

A phase I study of 5-fluorouracil, leucovorin and levamisole.

Cleary JF, Arzoomanian R, Alberti D, Feierabend C, Storer B, Witt P, Carbone P, Wilding G.

Cancer Chemother Pharmacol. 1997;39(4):300-6.

PMID:
9025770
25.

Phase I clinical trial of melphalan and 41.8 degrees C whole-body hyperthermia in cancer patients.

Robins HI, Rushing D, Kutz M, Tutsch KD, Tiggelaar CL, Paul D, Spriggs D, Kraemer C, Gillis W, Feierabend C, Arzoomanian RZ, Longo W, Alberti D, d'Oleire F, Qu RP, Wilding G, Stewart JA.

J Clin Oncol. 1997 Jan;15(1):158-64.

PMID:
8996137
26.

Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study.

McGinn CJ, Kunugi KA, Tutsch KD, Feierabend C, Alberti D, Lindstrom MJ, Wilding G, Arzoomanian RZ, Kinsella TJ.

Clin Cancer Res. 1996 Aug;2(8):1299-305.

27.

A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.

Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Spriggs D.

Semin Oncol. 1994 Oct;21(5 Suppl 8):9-14.

PMID:
7524159
28.

Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.

Schiller JH, Storer B, Tutsch K, Arzoomanian R, Alberti D, Feierabend C, Spriggs D.

J Clin Oncol. 1994 Feb;12(2):241-8.

PMID:
7509380
29.

Phase I clinical trial of carboplatin and 41.8 degrees C whole-body hyperthermia in cancer patients.

Robins HI, Cohen JD, Schmitt CL, Tutsch KD, Feierabend C, Arzoomanian RZ, Alberti D, d'Oleire F, Longo W, Heiss C, et al.

J Clin Oncol. 1993 Sep;11(9):1787-94.

PMID:
8355046
30.

Verrucous Haemangioma.

Mani MZ, Feierabend CT.

Indian J Dermatol Venereol Leprol. 1982 Mar-Apr;48(2):116-117.

Supplemental Content

Loading ...
Support Center